RxDoctor Payments Data

Sriram Krishnasamy, MD

Pulmonary Disease · Clarksville, TNNPI 1114024908

Payments from drug & device makers

$345in general payments, 2019–2025

Across 20 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$42
  • Boehringer Ingelheim$38
  • Actelion Pharmaceuticals US, Inc.$37
  • Insmed, Inc.$34
  • Abiomed$31
  • United Therapeutics Corporation$30
  • plus $133 from 8 others

What the payments were for

  • Food & beverage$27479%
  • Education$7121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$345 in reported general payments places this provider in the 20th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$206,122
Medicare patients
638
Services billed
2,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate70$928,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter341$378,783
AdempasRiociguat12$169,323
Spiriva RespimatTiotropium Bromide128$135,033
Dupixent PenDupilumab29$131,172
Breztri AerosphereBudesonide/Glycopyr/Formoterol106$103,206
Advair HfaFluticasone Propion/Salmeterol108$56,671
SymbicortBudesonide/Formoterol Fumarate127$49,228
Spiriva HandihalerTiotropium Bromide55$48,406
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$36,629
Fluticasone Propionate HfaFluticasone Propionate92$33,304
XareltoRivaroxaban54$29,440
Breo ElliptaFluticasone/Vilanterol38$25,232
EliquisApixaban25$24,835
Albuterol Sulfate HfaAlbuterol Sulfate852$23,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$38$1,074,824212 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$14$480,432492 claims
AstraZenecaBreztri Aerosphere, Symbicort$16$152,434233 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$11$13,91031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →